416 related articles for article (PubMed ID: 29203694)
21. Precision Oncology Decision Support: Current Approaches and Strategies for the Future.
Kurnit KC; Dumbrava EEI; Litzenburger B; Khotskaya YB; Johnson AM; Yap TA; Rodon J; Zeng J; Shufean MA; Bailey AM; Sánchez NS; Holla V; Mendelsohn J; Shaw KM; Bernstam EV; Mills GB; Meric-Bernstam F
Clin Cancer Res; 2018 Jun; 24(12):2719-2731. PubMed ID: 29420224
[TBL] [Abstract][Full Text] [Related]
22. Measuring Progress in Precision Oncology.
Horak P; Fröhling S
Cancer Discov; 2024 Jan; 14(1):18-19. PubMed ID: 38213297
[TBL] [Abstract][Full Text] [Related]
23. Harnessing the potential of reverse-phase protein array technology: Advancing precision oncology strategies.
Masuda M; Nakagawa R; Kondo T
Cancer Sci; 2024 May; 115(5):1378-1387. PubMed ID: 38409909
[TBL] [Abstract][Full Text] [Related]
24. Molecular Tumor Boards: Realizing Precision Oncology Therapy.
Patel M; Kato SM; Kurzrock R
Clin Pharmacol Ther; 2018 Feb; 103(2):206-209. PubMed ID: 29134641
[TBL] [Abstract][Full Text] [Related]
25. Implementing Precision Medicine Programs and Clinical Trials in the Community-Based Oncology Practice: Barriers and Best Practices.
Ersek JL; Black LJ; Thompson MA; Kim ES
Am Soc Clin Oncol Educ Book; 2018 May; 38():188-196. PubMed ID: 30231363
[TBL] [Abstract][Full Text] [Related]
26. [Precision Oncology and "Molecular Tumor Boards" - Concepts, Chances and Challenges].
Holch JW; Westphalen CB; Hiddemann W; Heinemann V; Jung A; Metzeler KH
Dtsch Med Wochenschr; 2017 Nov; 142(22):1676-1684. PubMed ID: 29078213
[TBL] [Abstract][Full Text] [Related]
27. Precision medicine clinical trials: defining new treatment strategies.
Heckman-Stoddard BM; Smith JJ
Semin Oncol Nurs; 2014 May; 30(2):109-16. PubMed ID: 24794084
[TBL] [Abstract][Full Text] [Related]
28. Precision medicine in oncology: what is it exactly and where are we?
Le Tourneau C; Kamal M; Bièche I
Per Med; 2018 Sep; 15(5):351-353. PubMed ID: 30260312
[No Abstract] [Full Text] [Related]
29. New clinical trial designs in the era of precision medicine: An overview of definitions, strengths, weaknesses, and current use in oncology.
Janiaud P; Serghiou S; Ioannidis JPA
Cancer Treat Rev; 2019 Feb; 73():20-30. PubMed ID: 30572165
[TBL] [Abstract][Full Text] [Related]
30. Efficacy of molecularly targeted agents given in the randomised trial SHIVA01 according to the ESMO Scale for Clinical Actionability of molecular Targets.
Moreira A; Masliah-Planchon J; Callens C; Vacher S; Lecerf C; Frelaut M; Borcoman E; Torossian N; Ricci F; Hescot S; Sablin MP; Tresca P; Loirat D; Melaabi S; Trabelsi-Grati O; Pierron G; Gentien D; Bernard V; Vincent Salomon A; Servant N; Bieche I; Le Tourneau C; Kamal M
Eur J Cancer; 2019 Nov; 121():202-209. PubMed ID: 31593830
[TBL] [Abstract][Full Text] [Related]
31. Precision medicine beyond medical oncology: using molecular analysis to guide treatments of colorectal neoplasia.
Molloy MP; Engel A
Expert Rev Gastroenterol Hepatol; 2018 Dec; 12(12):1179-1181. PubMed ID: 30791786
[No Abstract] [Full Text] [Related]
32. Delivering on the promise of precision cancer medicine.
Berger MF; Van Allen EM
Genome Med; 2016 Oct; 8(1):110. PubMed ID: 27782852
[No Abstract] [Full Text] [Related]
33. Lung cancer as a paradigm for precision oncology in solid tumours.
Schallenberg S; Merkelbach-Bruse S; Buettner R
Virchows Arch; 2017 Aug; 471(2):221-233. PubMed ID: 28730537
[TBL] [Abstract][Full Text] [Related]
34. Precision medicine in oncology: New practice models and roles for oncology pharmacists.
Walko C; Kiel PJ; Kolesar J
Am J Health Syst Pharm; 2016 Dec; 73(23):1935-1942. PubMed ID: 27864201
[TBL] [Abstract][Full Text] [Related]
35. Drug-biomarker co-development in oncology - 20 years and counting.
Twomey JD; Brahme NN; Zhang B
Drug Resist Updat; 2017 Jan; 30():48-62. PubMed ID: 28363335
[TBL] [Abstract][Full Text] [Related]
36. A clinical pharmacy pilot within a Precision Medicine Program for cancer patients and review of related pharmacist clinical practice.
Arnall JR; Petro R; Patel JN; Kennedy L
J Oncol Pharm Pract; 2019 Jan; 25(1):179-186. PubMed ID: 29078708
[TBL] [Abstract][Full Text] [Related]
37. Next-Generation Sequencing and Result Interpretation in Clinical Oncology: Challenges of Personalized Cancer Therapy.
Khotskaya YB; Mills GB; Mills Shaw KR
Annu Rev Med; 2017 Jan; 68():113-125. PubMed ID: 27813876
[TBL] [Abstract][Full Text] [Related]
38. Precision oncology: a clinical and patient perspective.
Lassen UN; Makaroff LE; Stenzinger A; Italiano A; Vassal G; Garcia-Foncillas J; Avouac B
Future Oncol; 2021 Oct; 17(30):3995-4009. PubMed ID: 34278817
[TBL] [Abstract][Full Text] [Related]
39. Universal Genomic Testing: The next step in oncological decision-making or a dead end street?
Holch JW; Metzeler KH; Jung A; Riedmann K; Jost PJ; Weichert W; Kirchner T; Heinemann V; Westphalen CB
Eur J Cancer; 2017 Sep; 82():72-79. PubMed ID: 28648701
[TBL] [Abstract][Full Text] [Related]
40. Precision Oncology in Pediatric Cancer Surgery.
Lee WG; Kim ES
Surg Oncol Clin N Am; 2024 Apr; 33(2):409-446. PubMed ID: 38401917
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]